DK3302437T3 - Stabile cannabinoidformuleringer - Google Patents
Stabile cannabinoidformuleringer Download PDFInfo
- Publication number
- DK3302437T3 DK3302437T3 DK16800777.1T DK16800777T DK3302437T3 DK 3302437 T3 DK3302437 T3 DK 3302437T3 DK 16800777 T DK16800777 T DK 16800777T DK 3302437 T3 DK3302437 T3 DK 3302437T3
- Authority
- DK
- Denmark
- Prior art keywords
- cannabinoid formulations
- stable cannabinoid
- stable
- formulations
- cannabinoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/724,351 US11224660B2 (en) | 2014-05-29 | 2015-05-28 | Stable cannabinoid formulations |
| US14/815,936 US11331279B2 (en) | 2014-05-29 | 2015-07-31 | Stable cannabinoid formulations |
| PCT/US2016/034565 WO2016191651A1 (en) | 2015-05-28 | 2016-05-27 | Stable cannabinoid formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3302437T3 true DK3302437T3 (da) | 2023-01-09 |
Family
ID=57393689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16800777.1T DK3302437T3 (da) | 2015-05-28 | 2016-05-27 | Stabile cannabinoidformuleringer |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4193990A1 (da) |
| JP (2) | JP6899506B2 (da) |
| AU (2) | AU2016267585C1 (da) |
| CA (1) | CA2986268C (da) |
| DK (1) | DK3302437T3 (da) |
| ES (1) | ES2938560T3 (da) |
| WO (1) | WO2016191651A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US10059683B2 (en) | 2015-07-10 | 2018-08-28 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
| CA3062814C (en) * | 2017-04-27 | 2023-11-14 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| WO2018232448A1 (en) * | 2017-06-19 | 2018-12-27 | Zelda Therapeutics Operations Pty Ltd | COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS |
| GB2564383B (en) * | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CA3075122A1 (en) * | 2017-09-15 | 2019-03-21 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| EP3840730B1 (en) | 2018-12-11 | 2023-09-20 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
| US20200375911A1 (en) * | 2019-06-03 | 2020-12-03 | Fresh Cut Development, Llc | Cannabidiol nanocrystal compositions |
| CA3152020C (en) * | 2019-09-09 | 2024-03-26 | Cardiol Therapeutics Inc. | Stable medicinal cannabidiol compositions |
| GB201918846D0 (en) * | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CA3201513A1 (en) * | 2020-12-07 | 2022-06-16 | Cardiol Therapeutics Inc. | Stable oral cannabidiol compositions |
| WO2022149144A1 (en) * | 2021-01-11 | 2022-07-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Stable efficient cosmetic preparations |
| GB2617823A (en) * | 2022-04-11 | 2023-10-25 | Chanelle Mccoy Cbd Ltd | A cannabidiol oil and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117773A (en) * | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
| AU730216B2 (en) * | 1996-09-01 | 2001-03-01 | Pharmos Corporation | Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| AU2002231970B2 (en) | 2001-02-14 | 2007-08-16 | GW Research Limited | Mucoadhesive pharmaceutical formulations |
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| WO2006063109A2 (en) * | 2004-12-09 | 2006-06-15 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
| US20140357708A1 (en) | 2005-11-07 | 2014-12-04 | Murty Pharmaceuticals, Inc. | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| WO2007056242A1 (en) * | 2005-11-07 | 2007-05-18 | Murty Pharmaceuticals, Inc. | Improved delivery of tetrahydrocannabinol |
| WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| WO2012071389A2 (en) | 2010-11-22 | 2012-05-31 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| US8741341B2 (en) * | 2012-05-07 | 2014-06-03 | Insys Therapeutics, Inc. | Manufacturing and packaging room temperature stable dronabinol capsules |
| DE102012105063C5 (de) | 2012-06-12 | 2023-09-14 | Thc Pharm Gmbh The Health Concept | Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen |
| US11331279B2 (en) * | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| EP4151234A1 (en) * | 2014-05-29 | 2023-03-22 | Fresh Cut Development, LLC | Stable cannabinoid formulations |
-
2016
- 2016-05-27 ES ES16800777T patent/ES2938560T3/es active Active
- 2016-05-27 CA CA2986268A patent/CA2986268C/en active Active
- 2016-05-27 AU AU2016267585A patent/AU2016267585C1/en active Active
- 2016-05-27 DK DK16800777.1T patent/DK3302437T3/da active
- 2016-05-27 JP JP2018513742A patent/JP6899506B2/ja active Active
- 2016-05-27 EP EP22207141.7A patent/EP4193990A1/en active Pending
- 2016-05-27 WO PCT/US2016/034565 patent/WO2016191651A1/en active Application Filing
- 2016-05-27 EP EP16800777.1A patent/EP3302437B8/en active Active
-
2021
- 2021-04-19 JP JP2021070161A patent/JP7374951B2/ja active Active
-
2022
- 2022-03-02 AU AU2022201441A patent/AU2022201441A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016191651A1 (en) | 2016-12-01 |
| JP6899506B2 (ja) | 2021-07-07 |
| JP7374951B2 (ja) | 2023-11-07 |
| EP3302437A4 (en) | 2018-12-05 |
| CA2986268C (en) | 2024-01-02 |
| EP3302437B1 (en) | 2022-11-16 |
| AU2022201441A1 (en) | 2022-03-24 |
| EP3302437B8 (en) | 2022-12-21 |
| CA2986268A1 (en) | 2016-12-01 |
| AU2016267585A1 (en) | 2017-11-30 |
| ES2938560T3 (es) | 2023-04-12 |
| EP3302437A1 (en) | 2018-04-11 |
| JP2018516281A (ja) | 2018-06-21 |
| EP4193990A1 (en) | 2023-06-14 |
| AU2016267585C1 (en) | 2023-02-16 |
| AU2016267585B2 (en) | 2021-12-16 |
| JP2021107438A (ja) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3688162T3 (da) | Formuleringer | |
| DK3302437T3 (da) | Stabile cannabinoidformuleringer | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| DK3331869T3 (da) | Muscarinagonister | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| FR3039337B1 (fr) | Motoreducteur compact | |
| DK3277719T3 (da) | Polypeptider | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3360890T3 (da) | Genterapi | |
| DK3331529T3 (da) | Muskarinagonister | |
| DK3310450T3 (da) | Olie-vand-separator | |
| MA50657A (fr) | Formulations de niraparib | |
| DK3226894T3 (da) | Stabile flydende vacciniavirus-formuleringer | |
| DK3163339T3 (da) | Polariseringsbevarende multikernefiber | |
| DK3270930T3 (da) | Præeklampsi | |
| DK3394281T3 (da) | Gærcelle | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DE112016003293A5 (de) | Feuerlöscher | |
| DE112015006486A5 (de) | Inkubationsrinne | |
| DK3318308T3 (da) | Badmintonketsjer | |
| DK3274482T3 (da) | Stenborsknop | |
| MA50068A (fr) | Formulations de copanlisib | |
| DE112016005599A5 (de) | Strahlungsgrill | |
| DE112015005904A5 (de) | Gurtschlossbringer | |
| ES1140083Y (es) | Descompatactador tetrafunción |